# Metformin for Abdominal Aortic Aneurysm Growth Inhibition

Study · id `cardio:ct-nct04224051` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04224051](<https://clinicaltrials.gov/study/NCT04224051>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04224051

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

## Technical summary

Registry record NCT04224051. Randomized; no masking; primary purpose treatment. Start 2020-02-12 (actual); primary completion 2026-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT04224051, source copy `cardio:ctgov-nct04224051-2023-09-06`, retrieved 2026-11-18)
- Started: 2020-02-12 (actual) (ClinicalTrials.gov record NCT04224051, source copy `cardio:ctgov-nct04224051-2023-09-06`, retrieved 2026-11-18)
- Primary completion: 2026-01 (anticipated) (ClinicalTrials.gov record NCT04224051, source copy `cardio:ctgov-nct04224051-2023-09-06`, retrieved 2026-11-18)
- Completion: 2026-01 (anticipated) (ClinicalTrials.gov record NCT04224051, source copy `cardio:ctgov-nct04224051-2023-09-06`, retrieved 2026-11-18)
- Countries: Sweden (ClinicalTrials.gov record NCT04224051, source copy `cardio:ctgov-nct04224051-2023-09-06`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04224051-2023-09-06`, retrieved 2026-11-18)

## The registry's words

- Brief title: Metformin for Abdominal Aortic Aneurysm Growth Inhibition
- Acronym: MAAAGI
- Condition: Abdominal Aortic Aneurysm
- Intervention (Drug): Metformin
- Intervention (Other): Standard care
- Lead sponsor: Uppsala University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Abdominal aortic aneurysm (`cardio:abdominal-aortic-aneurysm`)
- Registry condition terms include this condition: Aortic aneurysm (`cardio:aortic-aneurysm`)
- Registry lists this organization as the lead sponsor: Uppsala University Hospital (`cardio:org-uppsala-university-hospital`)

## Provenance

Content hash: bfac773fff484e7483942d6cb7d33efb81a202f4635b4e9f7ea271800269835c
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
